Product Center
The application for the marketing of trivalent influenza virus subunit vaccine has been accepted!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-10-08
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）has received acceptance from the Drug Evaluation Center (CDE) of the China National Medical Products Administration for its application to market the "6-35 month old trivalent influenza virus subunit vaccine" and the "3-year-old and above trivalent influenza virus subunit vaccine". This acceptance marks the final sprint stage of the first domestic full dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched!
The application for the marketing of trivalent influenza virus subunit vaccine has been accepted!
(Summary description)Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）has received acceptance from the Drug Evaluation Center (CDE) of the China National Medical Products Administration for its application to market the "6-35 month old trivalent influenza virus subunit vaccine" and the "3-year-old and above trivalent influenza virus subunit vaccine". This acceptance marks the final sprint stage of the first domestic full dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-10-08 11:33
- Views:
Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） has received acceptance from the Drug Evaluation Center (CDE) of the China National Medical Products Administration for its application to market the "6-35 month old trivalent influenza virus subunit vaccine" and the "3-year-old and above trivalent influenza virus subunit vaccine". This acceptance marks the final sprint stage of the first domestic full dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched!
Source: Government Service Website of the Drug Evaluation Center of the National Medical Products Administration
At present, influenza virus remains one of the important respiratory pathogens threatening human public health. Seasonal influenza outbreaks or occasional cross species transmission and pandemics of influenza virus have significant impacts on human health and socio-economic development. The WHO Influenza Vaccination Position Paper and the Chinese Center for Disease Control and Prevention's "Technical Guidelines for Influenza Vaccination in China" clearly state that annual influenza vaccination is the most economical and effective measure to prevent influenza, which can significantly reduce the risk of vaccine recipients contracting influenza and developing serious complications.
This year, WHO proposed that the global influenza surveillance network had not detected the B/Yamagata virus since March 2020, and therefore recommended that influenza vaccines should no longer include B/Yamagata lineage components. Ab&B Bio actively responded and acted quickly to complete the market application for the full dose trivalent influenza virus subunit vaccine for people aged 6 months and above, scientifically responding to influenza prevention and control, and providing a variety of influenza vaccine options for society. In addition, this vaccine is the first trivalent influenza virus subunit vaccine in China to achieve a unified dosage form for people aged 6 months and above, improving the convenience of influenza vaccine administration.
Ab&B Bio always insists on not making simple copies and deeply cultivates the field of subunit influenza technology. As of now, the Ab&B Bio subunit influenza vaccine family has covered: quadrivalent influenza virus subunit vaccines for people aged 6-35 months, quadrivalent influenza virus subunit vaccines for people aged 3 years and above, quadrivalent influenza virus subunit vaccines (adjuvants) for elderly people, trivalent influenza virus subunit vaccines for people aged 6 months and above, trivalent influenza virus subunit vaccines (adjuvants) for elderly people, and universal subunit influenza vaccines under development. The company adheres to the mission of caring for life and safeguarding health, and covers the needs of various populations with safe, effective, rich, and precise influenza vaccine series products to assist in influenza prevention and control.
Relevant information
-
Ab&B Bio and Yither Bio have both obtained qualification certification!Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) have been recognized as Jiangsu Province's specialized and innovative small and medium-sized enterprises and national high-tech enterprises, respectively. - The kickoff meeting for clinical research on the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome was successfully held 12-25
- Influenza virus subunit vaccine (adjuvant) IND application approved 10-30
- The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
